Focused On-demand Library for ATP-dependent RNA helicase DHX30

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q7L2E3

UPID:

DHX30_HUMAN

Alternative names:

DEAH box protein 30

Alternative UPACC:

Q7L2E3; A8K5F1; O94965; Q7Z753; Q96CH4; Q9NUQ0

Background:

ATP-dependent RNA helicase DHX30, also known as DEAH box protein 30, is pivotal in RNA processing and mitochondrial function. It acts as an RNA-dependent helicase, crucial for the assembly of the mitochondrial large ribosomal subunit, enhancing mitochondrial protein synthesis. DHX30's role extends to the regulation of the zinc-finger antiviral protein ZC3HAV1 and association with mitochondrial DNA, underpinning its importance in cellular antiviral responses and mitochondrial integrity.

Therapeutic significance:

DHX30's involvement in neurodevelopmental disorder with variable motor and language impairment highlights its therapeutic potential. Targeting DHX30 could lead to novel interventions for this disorder, emphasizing the importance of understanding its biological mechanisms for developing targeted therapies.